The following research was done using the next terms: MeSH Diabetes Mellitus type 2, Diabetic Nephropathy, Enterohormones, Incretins, GLP-1, Renoprotection
A 2024 analysis in Obesity from Prime Therapeutics followed 4,255 new GLP-1 starters and found that 68% discontinued within 12 months
However, once you already have lymphedema, the situation becomes more nuanced
Available for $99 as an add-on after your first month of treatment
The evidence for GLP-1 medications in treating NASH (the more severe form of fatty liver disease) is particularly impressive: Liraglutide achieved histological resolution of steatohepatitis in 39% of cases after 48 weeks, compared to just 9% in placebo groups 20 Patients taking liraglutide had 4.5 times higher likelihood of NASH resolution than those on placebo 20 Semaglutide demonstrated NASH resolution in 59% of participants versus 17% in placebo groups 21 We offer FibroScan technology to measure liver stiffness and fat content, helping us monitor your progress while on GLP-1 therapy
Therapeutic considerations include recognizing that weight loss with GLP-1 medications results from both peripheral metabolic effects and central appetite suppression
